The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells
Open accessAbstract
Cancer stem cells (CSCs) display plasticity and self-renewal properties reminiscent of normal tissue stem cells, but the events responsible for their emergence remain obscure. We recently identified CSCs in Ewing sarcoma family tumors (ESFTs) and showed that they retain mesenchymal stem cell (MSC) plasticity. In the present study, we addressed the mechanisms that underlie ESFT CSC development. We show that the EWS-FLI-1 fusion gene, associated with 85%–90% of ESFTs and believed to initiate their pathogenesis, induces expression of the embryonic stem cell (ESC) genes OCT4 , SOX2 , and NANOG in human pediatric MSCs (hpMSCs) but not in their adult counterparts. Moreover, under appropriate culture conditions, hpMSCs expressing EWS-FLI-1 generate a cell subpopulation displaying ESFT CSC features in vitro. We further demonstrate that induction of the ESFT CSC phenotype is the result of the combined effect of EWS-FLI-1 on its target gene expression and repression of microRNA-145 (miRNA145) promoter activity. Finally, we provide evidence that EWS-FLI-1 and miRNA-145 function in a mutually repressive feedback loop and identify their common target gene, SOX2 , in addition to miRNA145 itself, as key players in ESFT cell differentiation and tumorigenicity. Our observations provide insight for the first time into the mechanisms whereby a single oncogene can reprogram primary cells to display a CSC phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051
Neurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907 · cited 2×
“…translocation fuses the 59 end of the EWS gene to the 39 end of the FLI-1 gene, giving rise to the EWS-FLI-1 fusion protein where sequences containing the potent EWS transactivation domain are joined to sequences containing the DNAbinding domain (DBD) of FLI-1 (Delattre et al. 1992).”
BackgroundBreitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Stem Cells, the Molecular Circuitry of Pluripotency and Nuclear Reprogramming
Jaenisch, R., & Young, R. (2008) · Cell · doi:10.1016/j.cell.2008.01.015 · Cited by 1,427
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407 · cited 2×
“The anaplastic lymphoma kinase (ALK) is reported to be expressed in ESFTs (Dirks et al. 2002), and has been shown recently to be implicated in genetic predisposition to neuroblastoma development (Mosse et al. 2008).”
BackgroundSOX2 Functions to Maintain Neural Progenitor Identity
Graham, V., Khudyakov, J., Ellis, P., & Pevny, L. (2003) · Neuron · doi:10.1016/s0896-6273(03)00497-5 · Cited by 1,341
MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells
Xu, N., Papagiannakopoulos, T., Pan, G., Thomson, J. A., & Kosik, K. S. (2009) · Cell · doi:10.1016/j.cell.2009.02.038 · Cited by 1,124
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Epigenetic reprogramming in cancer
Suvà, M. L., Riggi, N., & Bernstein, B. E. (2013) · Science · doi:10.1126/science.1230184 · Cited by 706
Self-citationCancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Dedifferentiation and reprogramming: origins of cancer stem cells
Friedmann‐Morvinski, D., & Verma, I. M. (2014) · EMBO reports · doi:10.1002/embr.201338254 · Cited by 495
Riggi, N., Knoechel, B., Gillespie, S. M., Rheinbay, E., Boulay, G., Suvà, M. L., Rossetti, N. E., Boonseng, W. E., Oksuz, O., Cook, E. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.004 · Cited by 445
Self-citationBone Marrow Mesenchymal Stem Cells: Historical Overview and Concepts
Charbord, P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.115 · Cited by 441
Advances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3087 · Cited by 427
Riggi, N., Suvà, M. L., & Stamenkovic, I. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2028910 · Cited by 344
Self-citationSarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Cancer stem cells: problems for therapy?
Alison, M. R., Lim, S. M., & Nicholson, L. J. (2011) · The Journal of Pathology · doi:10.1002/path.2793 · Cited by 312
The multiple roles for Sox2 in stem cell maintenance and tumorigenesis
Liu, K., Lin, B., Zhao, M., Yang, X., Chen, M., Gao, A., Liu, F., Que, J., & Lan, X. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.02.013 · Cited by 263
SOX2 Regulates YAP1 to Maintain Stemness and Determine Cell Fate in the Osteo-Adipo Lineage
Seo, E., Basu-Roy, U., Gunaratne, P. H., Coarfa, C., Lim, D.-S., Basilico, C., & Mansukhani, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.029 · Cited by 216
“SOX2 expression is also seen in several undifferentiated cancers, including osteosarcomas (Bass et al., 2009; Basu-Roy et al., 2011; Riggi et al., 2010).”
BackgroundNatural product sciences: an integrative approach to the innovations of plant natural products
Shen, Y., & Hao, X. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1799-y · Cited by 37
Metadata
- Authors
- Riggi, N., Suvà, M.-L., De Vito, C., Provero, P., Stehle, J.-C., Baumer, K., Cironi, L., Janiszewska, M., Petricevic, T., Suvà, D., Tercier, S., Joseph, J.-M., Guillou, L., & Stamenkovic, I.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2010-04-09
- Volume
- 24
- Issue
- 9
- Pages
- 916-932
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2122271136
- Cited by
- 279
- References
- 51
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.